Literature DB >> 20200384

Glycated hemoglobin, diabetes, and cardiovascular risk in nondiabetic adults.

Elizabeth Selvin1, Michael W Steffes, Hong Zhu, Kunihiro Matsushita, Lynne Wagenknecht, James Pankow, Josef Coresh, Frederick L Brancati.   

Abstract

BACKGROUND: Fasting glucose is the standard measure used to diagnose diabetes in the United States. Recently, glycated hemoglobin was also recommended for this purpose.
METHODS: We compared the prognostic value of glycated hemoglobin and fasting glucose for identifying adults at risk for diabetes or cardiovascular disease. We measured glycated hemoglobin in whole-blood samples from 11,092 black or white adults who did not have a history of diabetes or cardiovascular disease and who attended the second visit (occurring in the 1990-1992 period) of the Atherosclerosis Risk in Communities (ARIC) study.
RESULTS: The glycated hemoglobin value at baseline was associated with newly diagnosed diabetes and cardiovascular outcomes. For glycated hemoglobin values of less than 5.0%, 5.0 to less than 5.5%, 5.5 to less than 6.0%, 6.0 to less than 6.5%, and 6.5% or greater, the multivariable-adjusted hazard ratios (with 95% confidence intervals) for diagnosed diabetes were 0.52 (0.40 to 0.69), 1.00 (reference), 1.86 (1.67 to 2.08), 4.48 (3.92 to 5.13), and 16.47 (14.22 to 19.08), respectively. For coronary heart disease, the hazard ratios were 0.96 (0.74 to 1.24), 1.00 (reference), 1.23 (1.07 to 1.41), 1.78 (1.48 to 2.15), and 1.95 (1.53 to 2.48), respectively. The hazard ratios for stroke were similar. In contrast, glycated hemoglobin and death from any cause were found to have a J-shaped association curve. All these associations remained significant after adjustment for the baseline fasting glucose level. The association between the fasting glucose levels and the risk of cardiovascular disease or death from any cause was not significant in models with adjustment for all covariates as well as glycated hemoglobin. For coronary heart disease, measures of risk discrimination showed significant improvement when glycated hemoglobin was added to models including fasting glucose.
CONCLUSIONS: In this community-based population of nondiabetic adults, glycated hemoglobin was similarly associated with a risk of diabetes and more strongly associated with risks of cardiovascular disease and death from any cause as compared with fasting glucose. These data add to the evidence supporting the use of glycated hemoglobin as a diagnostic test for diabetes. 2010 Massachusetts Medical Society

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20200384      PMCID: PMC2872990          DOI: 10.1056/NEJMoa0908359

Source DB:  PubMed          Journal:  N Engl J Med        ISSN: 0028-4793            Impact factor:   91.245


  42 in total

1.  Relationship of hemoglobin A1c to mortality in nonsmoking insurance applicants.

Authors:  Robert L Stout; Michael Fulks; Vera F Dolan; Mark E Magee; Luis Suarez
Journal:  J Insur Med       Date:  2007

2.  Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes.

Authors:  Anushka Patel; Stephen MacMahon; John Chalmers; Bruce Neal; Laurent Billot; Mark Woodward; Michel Marre; Mark Cooper; Paul Glasziou; Diederick Grobbee; Pavel Hamet; Stephen Harrap; Simon Heller; Lisheng Liu; Giuseppe Mancia; Carl Erik Mogensen; Changyu Pan; Neil Poulter; Anthony Rodgers; Bryan Williams; Severine Bompoint; Bastiaan E de Galan; Rohina Joshi; Florence Travert
Journal:  N Engl J Med       Date:  2008-06-06       Impact factor: 91.245

3.  Standards of medical care in diabetes--2009.

Authors: 
Journal:  Diabetes Care       Date:  2009-01       Impact factor: 19.112

Review 4.  Cardiovascular outcomes in trials of oral diabetes medications: a systematic review.

Authors:  Elizabeth Selvin; Shari Bolen; Hsin-Chieh Yeh; Crystal Wiley; Lisa M Wilson; Spyridon S Marinopoulos; Leonard Feldman; Jason Vassy; Renee Wilson; Eric B Bass; Frederick L Brancati
Journal:  Arch Intern Med       Date:  2008-10-27

5.  Racial and ethnic differences in mean plasma glucose, hemoglobin A1c, and 1,5-anhydroglucitol in over 2000 patients with type 2 diabetes.

Authors:  William H Herman; Kathleen M Dungan; Bruce H R Wolffenbuttel; John B Buse; Jessie L Fahrbach; Honghua Jiang; Sherry Martin
Journal:  J Clin Endocrinol Metab       Date:  2009-03-10       Impact factor: 5.958

6.  The hemoglobin A1c level as a progressive risk factor for cardiovascular death, hospitalization for heart failure, or death in patients with chronic heart failure: an analysis of the Candesartan in Heart failure: Assessment of Reduction in Mortality and Morbidity (CHARM) program.

Authors:  Hertzel C Gerstein; Karl Swedberg; Jonas Carlsson; John J V McMurray; Eric L Michelson; Bertil Olofsson; Marc A Pfeffer; Salim Yusuf
Journal:  Arch Intern Med       Date:  2008-08-11

7.  Effects of intensive glucose lowering in type 2 diabetes.

Authors:  Hertzel C Gerstein; Michael E Miller; Robert P Byington; David C Goff; J Thomas Bigger; John B Buse; William C Cushman; Saul Genuth; Faramarz Ismail-Beigi; Richard H Grimm; Jeffrey L Probstfield; Denise G Simons-Morton; William T Friedewald
Journal:  N Engl J Med       Date:  2008-06-06       Impact factor: 91.245

8.  HbA1c measured in stored erythrocytes and mortality rate among middle-aged and older women.

Authors:  E B Levitan; S Liu; M J Stampfer; N R Cook; K M Rexrode; P M Ridker; J E Buring; J E Manson
Journal:  Diabetologia       Date:  2007-11-28       Impact factor: 10.122

9.  Elevated A1C in adults without a history of diabetes in the U.S.

Authors:  Elizabeth Selvin; Hong Zhu; Frederick L Brancati
Journal:  Diabetes Care       Date:  2009-02-05       Impact factor: 19.112

10.  Diagnosis and classification of diabetes mellitus.

Authors: 
Journal:  Diabetes Care       Date:  2009-01       Impact factor: 19.112

View more
  513 in total

1.  Low hemoglobin A1c and risk of all-cause mortality among US adults without diabetes.

Authors:  April P Carson; Caroline S Fox; Darren K McGuire; Emily B Levitan; Martin Laclaustra; Devin M Mann; Paul Muntner
Journal:  Circ Cardiovasc Qual Outcomes       Date:  2010-10-05

2.  Glycated hemoglobin and cancer incidence and mortality in the Atherosclerosis in Communities (ARIC) Study, 1990-2006.

Authors:  Corinne E Joshu; Anna E Prizment; Paul J Dluzniewski; Andy Menke; Aaron R Folsom; Josef Coresh; Hsin C Yeh; Frederick L Brancati; Elizabeth A Platz; Elizabeth Selvin
Journal:  Int J Cancer       Date:  2012-02-10       Impact factor: 7.396

3.  De novo lipogenesis maintains vascular homeostasis through endothelial nitric-oxide synthase (eNOS) palmitoylation.

Authors:  Xiaochao Wei; Jochen G Schneider; Sherene M Shenouda; Ada Lee; Dwight A Towler; Manu V Chakravarthy; Joseph A Vita; Clay F Semenkovich
Journal:  J Biol Chem       Date:  2010-11-23       Impact factor: 5.157

4.  Heart disease and stroke statistics--2012 update: a report from the American Heart Association.

Authors:  Véronique L Roger; Alan S Go; Donald M Lloyd-Jones; Emelia J Benjamin; Jarett D Berry; William B Borden; Dawn M Bravata; Shifan Dai; Earl S Ford; Caroline S Fox; Heather J Fullerton; Cathleen Gillespie; Susan M Hailpern; John A Heit; Virginia J Howard; Brett M Kissela; Steven J Kittner; Daniel T Lackland; Judith H Lichtman; Lynda D Lisabeth; Diane M Makuc; Gregory M Marcus; Ariane Marelli; David B Matchar; Claudia S Moy; Dariush Mozaffarian; Michael E Mussolino; Graham Nichol; Nina P Paynter; Elsayed Z Soliman; Paul D Sorlie; Nona Sotoodehnia; Tanya N Turan; Salim S Virani; Nathan D Wong; Daniel Woo; Melanie B Turner
Journal:  Circulation       Date:  2011-12-15       Impact factor: 29.690

5.  Association of HbA1c levels with vascular complications and death in patients with type 2 diabetes: evidence of glycaemic thresholds.

Authors:  S Zoungas; J Chalmers; T Ninomiya; Q Li; M E Cooper; S Colagiuri; G Fulcher; B E de Galan; S Harrap; P Hamet; S Heller; S MacMahon; M Marre; N Poulter; F Travert; A Patel; B Neal; M Woodward
Journal:  Diabetologia       Date:  2011-12-21       Impact factor: 10.122

6.  Hyperglycemia and arterial stiffness: the Atherosclerosis Risk in the Communities study.

Authors:  Jonathan Rubin; Vijay Nambi; Lloyd E Chambless; Michael W Steffes; Stephen P Juraschek; Josef Coresh; A Richey Sharrett; Elizabeth Selvin
Journal:  Atherosclerosis       Date:  2012-09-13       Impact factor: 5.162

Review 7.  Insulin resistance, glucose intolerance and diabetes mellitus in obstructive sleep apnoea.

Authors:  Brian D Kent; Walter T McNicholas; Silke Ryan
Journal:  J Thorac Dis       Date:  2015-08       Impact factor: 2.895

Review 8.  Clinical significance of glycated hemoglobin in the acute phase of ST elevation myocardial infarction.

Authors:  Chiara Lazzeri; Serafina Valente; Marco Chiostri; Maria Grazia D'Alfonso; Gian Franco Gensini
Journal:  World J Cardiol       Date:  2014-04-26

9.  Label-free spectrochemical probe for determination of hemoglobin glycation in clinical blood samples.

Authors:  Rishikesh Pandey; Surya P Singh; Chi Zhang; Gary L Horowitz; Niyom Lue; Luis Galindo; Ramachandra R Dasari; Ishan Barman
Journal:  J Biophotonics       Date:  2018-06-19       Impact factor: 3.207

10.  Serum metabolomic profile of incident diabetes.

Authors:  Casey M Rebholz; Bing Yu; Zihe Zheng; Patrick Chang; Adrienne Tin; Anna Köttgen; Lynne E Wagenknecht; Josef Coresh; Eric Boerwinkle; Elizabeth Selvin
Journal:  Diabetologia       Date:  2018-03-20       Impact factor: 10.122

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.